NASDAQ:LFCR

Lifecore Biomedical (LFCR) Stock Forecast, Price & News

$7.58

-0.34 (-4.29%)

(As of 09/27/2023 ET)

Compare

Today's Range: $7.53
▼
$8.00
50-Day Range: $7.47
▼
$10.84
52-Week Range: $1.52
▼
$11.45

Volume: 225,254 shs
Average Volume: 579,380 shs
Market Capitalization: $229.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.50

Lifecore Biomedical MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 25.3% Upside
$9.50 Price Target
Short Interest: Bearish
6.77% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.14
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.06) to $0.58 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

708th out of 976 stocks

Pharmaceutical Preparations Industry

332nd out of 456 stocks

3.3

Analyst's Opinion

Consensus Rating
Lifecore Biomedical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.50, Lifecore Biomedical has a forecasted upside of 25.3% from its current price of $7.58.
Amount of Analyst Coverage
Lifecore Biomedical has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.77% of the float of Lifecore Biomedical has been sold short.
Short Interest Ratio / Days to Cover
Lifecore Biomedical has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in Lifecore Biomedical has recently increased by 11.67%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Lifecore Biomedical does not currently pay a dividend.
Dividend Growth
Lifecore Biomedical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LFCR.

2.9

News and Social Media Coverage

News Sentiment
Lifecore Biomedical has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Lifecore Biomedical this week, compared to 1 article on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lifecore Biomedical insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.61% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.85% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.06) to $0.58 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lifecore Biomedical is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lifecore Biomedical is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lifecore Biomedical has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lifecore Biomedical (NASDAQ:LFCR) Stock

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is based in Chaska, Minnesota.

LFCR Price History

30 days | 90 days | 365 days | Advanced Chart

LFCR Stock News Headlines

September 21, 2023 | fool.com

Lifecore Biomedical (NASDAQ: LFCR)

September 5, 2023 | msn.com

Lifecore Biomedical: Quality CDMO, Potential Sale

September 27, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 1, 2023 | finance.yahoo.com

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q4 2023 Earnings Call Transcript

September 1, 2023 | finance.yahoo.com

Q4 2023 Lifecore Biomedical Inc Earnings Call

August 31, 2023 | finanznachrichten.de

Lifecore Biomedical, Inc.: Lifecore Biomedical Reports Fourth Quarter and Full Fiscal Year 2023 Results

August 31, 2023 | sfgate.com

Lifecore Biomedical: Fiscal Q4 Earnings Snapshot

August 31, 2023 | finance.yahoo.com

Lifecore Biomedical Reports Fourth Quarter and Full Fiscal Year 2023 Results

September 27, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

August 31, 2023 | finance.yahoo.com

Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates

August 22, 2023 | msn.com

Lifecore Biomedical gets Nasdaq noncompliance notice

August 22, 2023 | finance.yahoo.com

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report

August 22, 2023 | finance.yahoo.com

Lifecore Biomedical Sets Fourth Quarter 2023 Earnings Conference Call for August 31, 2023 at 7:30 a.m. CT

August 18, 2023 | finance.yahoo.com

New York Times and OneSpan Stock See Action From Activist Investors

August 17, 2023 | finance.yahoo.com

Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates

August 16, 2023 | finance.yahoo.com

Cove Street Capital, LLC Reduces Stake in Lifecore Biomedical Inc

August 12, 2023 | msn.com

Greenhaven Road Capital - Lifecore Biomedical: Gem Of A CDMO Business

August 12, 2023 | finance.yahoo.com

Do You Think Lifecore Biomedical (LFCR) Will Get Sold for a Healthy Premium?

July 31, 2023 | finance.yahoo.com

Lifecore Biomedical (LFCR) Does Not Face Bankruptcy Risk Now

July 22, 2023 | finance.yahoo.com

Lifecore Biomedical (NASDAQ:LFCR) investors are sitting on a loss of 26% if they invested five years ago

June 29, 2023 | finance.yahoo.com

Institutional investors own a significant stake of 43% in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

June 27, 2023 | msn.com

Lifecore: Highly Skewed Special Situation

June 8, 2023 | finance.yahoo.com

What Makes Lifecore Biomedical (LFCR) an Attractive Investment Opportunity?

June 5, 2023 | barrons.com

Lifecore Biomedical Inc.

June 3, 2023 | finance.yahoo.com

Lifecore Biomedical Third Quarter 2023 Earnings: Misses Expectations

June 1, 2023 | msn.com

Recap: Lifecore Biomedical Q3 Earnings

June 1, 2023 | apnews.com

Lifecore Biomedical: Fiscal Q3 Earnings Snapshot

See More Headlines

Receive LFCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter.

LFCR Company Calendar

Last Earnings: 8/31/2023
Today: 9/27/2023
Next Earnings (Estimated): 10/05/2023
Fiscal Year End: 5/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LFCR
CUSIP: N/A
CIK: 1005286
Web: www.lifecore.com
Phone: (800) 454-1355
Fax: 650-368-9818
Employees: 689
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.50
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +25.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-102,190,000.00
Net Margins: -71.36%
Pretax Margin: -59.59%
Return on Equity: -79.34%
Return on Assets: -19.09%

Debt

Debt-to-Equity Ratio: 3.36
Current Ratio: 2.35
Quick Ratio: 1.05

Sales & Book Value

Annual Sales: $103.27 million
Price / Sales: 2.23
Cash Flow: $3.93 per share
Price / Cash Flow: 1.93
Book Value: $3.08 per share
Price / Book: 2.46

Miscellaneous

Outstanding Shares: 30,320,000
Free Float: 25,892,000
Market Cap: $229.83 million
Optionable: Optionable
Beta: 1.13

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. James G. Hall (Age 60)
CEO, Pres & Director
Comp: $711.57k

Mr. John D. Morberg (Age 59)
Exec. VP & CFO
Comp: $443.43k

Dr. Albert D. Bolles Ph.D. (Age 65)
Pres of Curation Foods, Inc.
Comp: $688.19k

Mr. Steve W. Laninga
VP of Operations

Dr. Kipling Thacker Ph.D. (Age 68)
VP & Chief Scientist

Mr. Aaron Perlitsh
Director of Internal Audit & Chief Compliance Officer

Mr. Darren M. Hieber
Sr. VP of Corp. Devel. & Partnerships

Ms. Kara Morley
Sr. VP of HR

Ms. Jackie Q. Klecker
Exec. VP & GM

Mr. Matt Augustson
Sr. VP of Information Technology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LFCR Stock - Frequently Asked Questions

Should I buy or sell Lifecore Biomedical stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lifecore Biomedical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LFCR shares.
View LFCR analyst ratings or view top-rated stocks.
What is Lifecore Biomedical's stock price forecast for 2023?: 2 Wall Street analysts have issued 12 month target prices for Lifecore Biomedical's stock. Their LFCR share price forecasts range from $9.00 to $10.00. On average, they predict the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 25.3% from the stock's current price.
View analysts price targets for LFCR or view top-rated stocks among Wall Street analysts.
How have LFCR shares performed in 2023?: Lifecore Biomedical's stock was trading at $6.48 at the beginning of 2023. Since then, LFCR shares have increased by 17.0% and is now trading at $7.58.
View the best growth stocks for 2023 here.
Are investors shorting Lifecore Biomedical?: Lifecore Biomedical saw a increase in short interest in September. As of September 15th, there was short interest totaling 2,010,000 shares, an increase of 11.7% from the August 31st total of 1,800,000 shares. Based on an average daily volume of 266,900 shares, the short-interest ratio is currently 7.5 days. Approximately 6.8% of the shares of the stock are sold short.
View Lifecore Biomedical's Short Interest.
When is Lifecore Biomedical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 5th 2023.
View our LFCR earnings forecast.
How were Lifecore Biomedical's earnings last quarter?: Lifecore Biomedical, Inc. (NASDAQ:LFCR) issued its earnings results on Thursday, August, 31st. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.82. The company earned $31.55 million during the quarter, compared to analyst estimates of $28.99 million. Lifecore Biomedical had a negative trailing twelve-month return on equity of 79.34% and a negative net margin of 71.36%.

What is Lifecore Biomedical's stock symbol?: Lifecore Biomedical trades on the NASDAQ under the ticker symbol "LFCR."
Who are Lifecore Biomedical's major shareholders?: Lifecore Biomedical's stock is owned by a number of retail and institutional investors. Top institutional investors include Wynnefield Capital Inc. (16.24%), Cove Street Capital LLC (5.34%), BlackRock Inc. (1.75%), Visionary Wealth Advisors (1.65%), Geode Capital Management LLC (0.95%) and Royal Bank of Canada (0.48%).
How do I buy shares of Lifecore Biomedical?: Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lifecore Biomedical's stock price today?: One share of LFCR stock can currently be purchased for approximately $7.58.
How much money does Lifecore Biomedical make?: Lifecore Biomedical (NASDAQ:LFCR) has a market capitalization of $229.83 million and generates $103.27 million in revenue each year. The company earns $-102,190,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.
How many employees does Lifecore Biomedical have?: The company employs 689 workers across the globe.
How can I contact Lifecore Biomedical?: Lifecore Biomedical's mailing address is 2811 AIRPARK DRIVE, SANTA MARIA CA, 93455. The official website for the company is www.lifecore.com. The company can be reached via phone at (800) 454-1355, via email at jeff.sonnek@icrinc.com, or via fax at 650-368-9818.

This page (NASDAQ:LFCR) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial